Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
HCQ Use May Reduce Risk of CV Events
01/11/2022
Among patients with rheumatoid arthritis and systemic lupus erythematosus, recent use of hydroxychloroquine was associated with lower risk of some cardiovascular complications.
Among patients with rheumatoid arthritis and systemic lupus erythematosus, recent use of hydroxychloroquine was associated with lower risk of some cardiovascular complications.
Among patients with rheumatoid...
01/11/2022
Autoimmune

Advertisement

News
SLE Disease Flare Less Likely With HCQ Maintenance
01/06/2022
Patients with systemic lupus erythematosus were more likely to experience a flare following hydroxychloroquine (HCQ) taper/discontinuation when compared to patients on HCQ maintenance.
Patients with systemic lupus erythematosus were more likely to experience a flare following hydroxychloroquine (HCQ) taper/discontinuation when compared to patients on HCQ maintenance.
Patients with systemic lupus...
01/06/2022
Autoimmune
News
Some Patients Classified With UCTD Meet Criteria for SLE
01/06/2022
Applying the 2019 EULAR/ACR criteria to patients reveals that some actually have systemic lupus erythematosus rather than undifferentiated connective tissue disease.
Applying the 2019 EULAR/ACR criteria to patients reveals that some actually have systemic lupus erythematosus rather than undifferentiated connective tissue disease.
Applying the 2019 EULAR/ACR...
01/06/2022
Autoimmune
News
Dactylitis Useful in Risk Stratification for PsA
01/05/2022
Researchers found that patients with early psoriatic arthritis who were naïve to disease-modifying antirheumatic drugs and present with dactylitis could have more severe disease.
Researchers found that patients with early psoriatic arthritis who were naïve to disease-modifying antirheumatic drugs and present with dactylitis could have more severe disease.
Researchers found that patients...
01/05/2022
Rheumatology & Arthritis

Advertisement

News
Proactive TDM Superior to Standard Therapy Among Patients IMIDs
01/03/2022
Patients with immune-mediated inflammatory disease on maintenance infliximab therapy achieved better sustained disease control with proactive therapeutic drug monitoring.
Patients with immune-mediated inflammatory disease on maintenance infliximab therapy achieved better sustained disease control with proactive therapeutic drug monitoring.
Patients with immune-mediated...
01/03/2022
Rheumatology & Arthritis
News
FDA Approves Tofacitinib for Ankylosing Spondylitis
12/21/2021
The US Food and Drug Administration has approved tofacitinib for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.
The US Food and Drug Administration has approved tofacitinib for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.
The US Food and Drug...
12/21/2021
Autoimmune
News
South Korea Reports Unprecedented Decline in Behçet Disease in Recent Years
12/20/2021
A recent study has showed that between 2004 and 2017, the incidence of Behçet disease decreased 81.5% in South Korea.
A recent study has showed that between 2004 and 2017, the incidence of Behçet disease decreased 81.5% in South Korea.
A recent study has showed that...
12/20/2021
Autoimmune

Advertisement

News
Phase 3 Trial Confirms Efficacy and Safety of Voclosporin in Lupus Nephritis
12/17/2021
The addition of voclosporin to mycophenolate mofetil (MMF) and low-dose steroids proved superior to MMF and steroids alone in achieving complete renal response.
The addition of voclosporin to mycophenolate mofetil (MMF) and low-dose steroids proved superior to MMF and steroids alone in achieving complete renal response.
The addition of voclosporin to...
12/17/2021
Autoimmune
News
Potential for Severe COVID-19 Outcomes Among Patients With Vasculitis
12/05/2021
According to a recent study, risk factors associated with systemic vasculitis or polymyalgia rheumatica could lead to poor COVID-19 outcomes.
According to a recent study, risk factors associated with systemic vasculitis or polymyalgia rheumatica could lead to poor COVID-19 outcomes.
According to a recent study,...
12/05/2021
Autoimmune
News
COVID-19 Outcomes No Worse for Patients on Most Immunosuppressive Medicines
12/03/2021
A recent study found that, with the exception of rituximab, none of the immunosuppressive therapies included in the study were associated with increased risks of worse COVID-19 outcomes.
A recent study found that, with the exception of rituximab, none of the immunosuppressive therapies included in the study were associated with increased risks of worse COVID-19 outcomes.
A recent study found that, with...
12/03/2021
Autoimmune

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Popular Articles

News
Lupus: Predictors of Poor Outcomes Following Hydroxychloroquine Tapering, Discontinuation Are Identified
01/14/2021
Researchers have determined that several demographic and clinical factors are associated with poor outcomes after hydroxychloroquine tapering or discontinuation. Find out what these factors are.
Researchers have determined that several demographic and clinical factors are associated with poor outcomes after hydroxychloroquine tapering or discontinuation. Find out what these factors are.
Researchers have determined that...
01/14/2021
Autoimmune
News
How Common Are Musculoskeletal Manifestations Among Patients With IBD Receiving Vedolizumab?
11/13/2020
The researchers determined the percentage of patients with musculoskeletal manifestations and whether those manifestations were mechanical or inflammatory.
The researchers determined the percentage of patients with musculoskeletal manifestations and whether those manifestations were mechanical or inflammatory.
The researchers determined the...
11/13/2020
Autoimmune
News
Risk of Serious Infection, Glucocorticoid Use Are Linked Among Patients With RA
09/29/2020
While low-dose glucocorticoids are commonly used in the management of rheumatoid arthritis, the safety of the medications’ long-term use is unclear. Researchers evaluated the association between long-term low-dose glucocorticoid use and risk...
While low-dose glucocorticoids are commonly used in the management of rheumatoid arthritis, the safety of the medications’ long-term use is unclear. Researchers evaluated the association between long-term low-dose glucocorticoid use and risk...
While low-dose glucocorticoids...
09/29/2020
Autoimmune
Poll
Pop Quiz: Autoimmune Protocol Diet
08/13/2020
A few studies have assessed the efficacy of the autoimmune protocol diet among patients with inflammatory bowel disease and Hashimoto thyroiditis. This anti-inflammatory diet is very restrictive. Which of the following foods are allowed on...
A few studies have assessed the efficacy of the autoimmune protocol diet among patients with inflammatory bowel disease and Hashimoto thyroiditis. This anti-inflammatory diet is very restrictive. Which of the following foods are allowed on...
A few studies have assessed the...
08/13/2020
Autoimmune
Exclusive Preview: Biosimilars for IMIDs: Availability, Affordability, and Interchangeability
Conference Coverage
Exclusive Preview: Biosimilars for IMIDs: Availability, Affordability, and Interchangeability
07/10/2020
In this short video from IAS 2020, Jonathan Kay, MD, summarizes why biosimilar use may be limited in the United States in his presentation, "Biosimilars for IMIDs: Availability, Affordability, and Interchangeability."
In this short video from IAS 2020, Jonathan Kay, MD, summarizes why biosimilar use may be limited in the United States in his presentation, "Biosimilars for IMIDs: Availability, Affordability, and Interchangeability."
In this short video from IAS...
07/10/2020
Autoimmune

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Stay In the Know

Autoimmune Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use